ArticleJournal of registry management2024
An Examination of Liver Cancer Incidence in California.
Article in Journal of registry management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999-2024: a CDC WONDER analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background and Objective: Liver cancer is composed of 2 main types, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). After years of increasing HCC incidence rates in the United States, declines have been noted in recent years, but CCA incidence rates have continued increasing. Given these variable trends; documented disparities by sex, age, and race/ethnicity; and shifting risk factors from viral infection (hepatitis B and C) to metabolic causes (obesity, diabetes, nonalcoholic fatty liver disease), we sought to assess the incidence rate trends for HCC and CCA in California to inform whether California trends are similar to those observed in the United States as a whole, whether these trends have continued in the most recent years for which data is available, and to identify at-risk groups that may benefit from targeted intervention. Methods: Using SEER*Stat software, we calculated age-adjusted incidence rates (AAIR) by sex, age group, and race/ethnicity for patients aged ≥40 years diagnosed with HCC and CCA from 2010 to 2021 identified in the California Cancer Registry. We assessed the annual percent change (APC) over this period for each subgroup using Joinpoint software. Results: For HCC, the AAIR significantly decreased for men (-2.68%) and women (-2.23%) since 2014. Significant decreases were observed for men among all racial/ethnic groups, but among women, decreases were only seen in Black and Asian/Pacific Islander patients. Decreases in AAIR were greatest among those aged 40 to 64 years (men, -7.01%; women, -7.79%) and increases were observed for men aged ≥75 years since 2010 (1.15%). For CCA, the AAIR significantly increased for men aged ≥75 years (2.8%) and for women in all age groups. Only White men had decreasing AAIRs. Conclusion: HCC AAIR trends have declined in California, but not for all groups. Older men and Hispanic and White women did not experience the same reductions in HCC AAIR observed in other groups. CCA AAIR trends have increased among nearly all groups for women. Future research should focus on evaluating risk factors by liver cancer sub-type, and regular screening of individuals with risk factors should be considered.
Indexed as
Identifiers
40109759PMC11917983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.